Enrichment of Nur77 mediated by retinoic acid receptor β leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors

Hui Yang, Qi Zhan, Yu‐Jui Yvonne Wan – 7 December 2010 – The synthetic retinoid fenretinide is one of the most promising clinically tested retinoids. Previously, we have shown that fenretinide induces apoptosis of Huh7 cells, but HepG2 cells are relatively resistant to fenretinide‐induced apoptosis. This study examines the interactive role of fenretinide and histone deacetylase inhibitors (HDACi) in inducing apoptosis of human hepatocellular carcinoma (HCC) cells and the underlying mechanism.

Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol‐induced oxidative injury in mouse liver

Soo Han Bae, Su Haeng Sung, Eun Jung Cho, Se Kyoung Lee, Hye Eun Lee, Hyun Ae Woo, Dae‐Yeul Yu, In Sup Kil, Sue Goo Rhee – 7 December 2010 – Peroxiredoxins (Prxs) are peroxidases that catalyze the reduction of reactive oxygen species (ROS). The active site cysteine residue of members of the 2‐Cys Prx subgroup (Prx I to IV) of Prxs is hyperoxidized to cysteine sulfinic acid (Cys‐SO2) during catalysis with concomitant loss of peroxidase activity. Reactivation of the hyperoxidized Prx is catalyzed by sulfiredoxin (Srx).

Interleukin‐10–mediated heme oxygenase 1–induced underlying mechanism in inflammatory down‐regulation by norfloxacin in cirrhosis

Isabel Gómez‐Hurtado, Pedro Zapater, Pablo Bellot, Sonia Pascual, Miguel Pérez‐Mateo, José Such, Rubén Francés – 7 December 2010 – Patients with cirrhosis receiving norfloxacin show a restored inflammatory balance that likely prevents clinical complications derived from an excessive proinflammatory response to bacterial product challenges. This study sought to investigate associated inflammatory control mechanisms established in patients with cirrhosis receiving norfloxacin. A total of 62 patients with cirrhosis and ascites in different clinical conditions were considered.

Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis

Tim O. Lankisch, Jochen Metzger, Ahmed A. Negm, Katja Voβkuhl, Eric Schiffer, Justyna Siwy, Tobias J. Weismüller, Andrea S. Schneider, Kathrin Thedieck, Ralf Baumeister, Petra Zürbig, Eva M. Weissinger, Michael P. Manns, Harald Mischak, Jochen Wedemeyer – 7 December 2010 – Early detection of malignant biliary tract diseases, especially cholangiocarcinoma (CC) in patients with primary sclerosing cholangitis (PSC), is very difficult and often comes too late to give the patient a therapeutic benefit. We hypothesize that bile proteomic analysis distinguishes CC from nonmalignant lesions.

Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection

Marie‐Luise Berres, Christian Trautwein, Maximilian Schmeding, Dennis Eurich, Frank Tacke, Marcus Bahra, Peter Neuhaus, Ulf P. Neumann, Hermann E. Wasmuth – 6 December 2010 – The recurrence of liver fibrosis after liver transplantation (LT) for hepatitis C virus (HCV) infection is responsible for graft loss and patient mortality. Although the contribution of the immune system to fibrosis recurrence is anticipated, systematic studies evaluating immune parameters as predictive markers of allograft fibrosis are lacking.

Gender‐specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease

Oyekoya T. Ayonrinde, John K. Olynyk, Lawrence J. Beilin, Trevor A. Mori, Craig E. Pennell, Nicholas de Klerk, Wendy H. Oddy, Peter Shipman, Leon A. Adams – 6 December 2010 – Nonalcoholic fatty liver disease (NAFLD) is a predominantly adult‐diagnosed disorder. Knowledge regarding the epidemiology, phenotype, and metabolic risk factors, during adolescence is limited.

Relationship between the interleukin‐28b gene polymorphism and the histological severity of hepatitis C virus–induced graft inflammation and the response to antiviral therapy after liver transplantation

Dennis Eurich, Sabine Boas‐Knoop, Martin Ruehl, Maria Schulz, Esperanza D. Carrillo, Thomas Berg, Ruth Neuhaus, Peter Neuhaus, Ulf Peter Neumann, Marcus Bahra – 6 December 2010 – Up to 30% of liver transplants will develop graft cirrhosis within 5 years after liver transplantation (LT) due to recurrent HCV‐infection forwarding accelerated graft damage. Genetic variants of cytokines involved in the immune response may contribute to the degree of graft inflammation, fibrosis progression, and antiviral therapy outcome.

Subscribe to